Menu
Recruiting NCT07487272

Single-cell and Spatial Transcriptomic Profiling of Gingival Tissues in Aggressive and Chronic Periodontitis: Deciphering Cellular Heterogeneity and Inflammatory Microenvironment Features

— Observational Periodontis Aggressive Periodontitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Periodontis, Aggressive Periodontitis. Basic parameters: 20 years — 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The goal of this observational study is to investigate cellular heterogeneity and inflammatory microenvironment features in gingival tissues from patients with aggressive periodontitis compared to chronic periodontitis and healthy controls, using single-cell and spatial transcriptomics combined with whole-genome sequencing. The main question(s) it aims to answer are: What are the differences in cellular composition, mesenchymal stem cell subpopulations, and gene expression profiles between aggressive periodontitis, chronic periodontitis, and healthy gingival tissues? Which key molecular markers, signaling pathways, and spatially resolved microenvironment patterns distinguish aggressive periodontitis from the more common chronic form? Are there disease-specific genetic variants associated with aggressive periodontitis identified through whole-genome sequencing of peripheral blood DNA? Participants (already scheduled for tooth extraction or periodontal surgery as part of routine clinical care) will undergo: Standard clinical periodontal examination and CBCT imaging Collection of a small gingival tissue sample (\~1×3×1 mm) during the planned extraction/surgery under local anesthesia Collection of 5 mL peripheral blood for DNA extraction No additional intervention, treatment, or follow-up visit is required beyond routine dental care. Last updated: December 23, 2025

Primary outcome measures

  • Landscape of Cellular Heterogeneity in Periodontal Tissues [Time frame: 1 year]
  • Identification of Key Molecular Markers and Signaling Pathways [Time frame: 1 year]
Secondary outcome measures (2)
  • Spatial Transcriptomic Expression Profiles [Time frame: 1 year]
  • Genetic Variants Identified by Whole-Genome Sequencing [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

Aggressive Periodontitis Patients:

  • Aged 20-35 years
  • Radiographic evidence of at least 30% vertical bone loss at ≥2 tooth sites
  • Can be classified as Stage III/IV, Grade C periodontitis according to the 2018 new classification of periodontitis
  • With or without family history of periodontitis
  • No significant local contributing factors (e.g., calculus, occlusal trauma, etc.)

Chronic Periodontitis Patients:

  • Aged 30-40 years
  • ≥3 sites with probing depth ≥5 mm
  • Can be classified as Stage I/II, Grade A/B periodontitis according to the 2018 new classification of periodontitis
  • No significant family history
  • Disease predominantly driven by local factors (dental plaque, calculus, etc.)

Healthy Controls:

  • Aged 20-40 years
  • Radiographic examination shows no significant alveolar bone loss
  • Clinically cannot be diagnosed with gingivitis or periodontitis

Exclusion criteria

  • Use of antibiotics within the past 3 months
  • Smoking >10 cigarettes per day
  • Uncontrolled severe diabetes (HbA1c level ≥6.7%)
  • Planning pregnancy, currently pregnant, or breastfeeding
  • Alcohol or drug addiction
  • Long-term use of immunosuppressive agents
  • Infectious diseases such as hepatitis or AIDS/HIV
  • History of malignant tumor, radiotherapy, or chemotherapy within the past 5 years

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Other

Study locations

China · 1 center
  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China — Hangzhou

Identifiers

NCT: NCT07487272 · 2025-1735

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗